Skip to content

Novel Technique for Botulinum Toxin Injection to Minimize Patient Discomfort

Novel Technique for Botulinum Toxin Injection to Minimize Patient Discomfort

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00628472
Enrollment
21
Registered
2008-03-05
Start date
2007-01-31
Completion date
2007-05-31
Last updated
2024-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

botulinum toxin a, botox, Decreasing botox injection pain, injections

Brief summary

This single blinded randomized pilot study was performed on 21 Caucasian females to determine if injections through follicular openings were less painful than traditional injections for cosmetic botulinum toxin type A injections.

Detailed description

Objective: To investigate whether injection of botulinum toxin type A is less painful if performed through follicular openings versus traditional non-specific approach. Design: Prospective, randomized, single-blinded study. Setting: Academic dermatology department. Patients: A volunteer sample of twenty female patients aged 25-55 who had no prior history of botulinum toxin injection. Intervention: Each patient received six randomized injections of botulinum toxin type A (Botox® Allergan). Two injections into the procerus muscle and two into each corrugator muscle. Three of the injections were performed through follicular openings and three were performed traditionally. Main Outcome Measure: Patient discomfort on a 1-10 scale and direct comparison between the two injection techniques.

Interventions

12 Units total were injected into 6 sites in the glabellar complex to determine if injecting through the follicle versus a traditional approach would decrease patient discomfort

Sponsors

Henry Ford Health System
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Female * No prior history of botulinum toxin * Age 25-55

Exclusion criteria

* Male * Prior history of botulinum toxin * Neuromuscular disorders * Aminoglycoside therapy

Design outcomes

Primary

MeasureTime frame
Decrease pain on injection for treatment intervention assessed on a 10 point scaleAt time of intervention

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026